VRDN Viridian Therapeutics Inc

EMERYVILLE, Calif., Nov. 17, 2025 ( GLOBE NEWSWIRE ) -- 4D Molecular Therapeutics ( Nasdaq: FDMT, 4DMT or the Company ) , a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented ...

EMERYVILLE, Calif., Nov. 17, 2025 ( GLOBE NEWSWIRE ) -- 4D Molecular Therapeutics ( NASDAQ:FDMT, 4DMT or the Company ) ) , a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented ...

Exton, PA, Nov. 12, 2025 ( GLOBE NEWSWIRE ) -- New research from Spherix Global Insights finds that while Amgen's Tepezza ( teprotumumab ) continues to anchor the treatment landscape for thyroid eye disease ( TED ) , physicians emphasize ongoing unmet needs-particularly for patients with milder ...

Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of +58.54% and +50.85%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Viridian Therapeutics (VRDN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Viridian Therapeutics, Inc. VRDN reported upbeat results for the second quarter on Wednesday. The company posted quarterly losses of $ ( 1.00 ) per share which beat the analyst consensus estimate of $ ( 1.02 ) per share.